TGR5 Activation Promotes Stimulus-Secretion Coupling of Pancreatic β-Cells Via a PKA-Dependent Pathway
Overview
Authors
Affiliations
The Takeda-G-protein-receptor-5 (TGR5) mediates physiological actions of bile acids. Since it was shown that TGR5 is expressed in pancreatic tissue, a direct TGR5 activation in β-cells is currently postulated and discussed. The current study reveals that oleanolic acid (OLA) affects murine β-cell function by TGR5 activation. Both a G inhibitor and an inhibitor of adenylyl cyclase (AC) prevented stimulating effects of OLA. Accordingly, OLA augmented the intracellular cAMP concentration. OLA and two well-established TGR5 agonists, RG239 and tauroursodeoxycholic acid (TUDCA), acutely promoted stimulus-secretion coupling (SSC). OLA reduced K current and elevated current through Ca channels. Accordingly, in mouse and human β-cells, TGR5 ligands increased the cytosolic Ca concentration by stimulating Ca influx. Higher OLA concentrations evoked a dual reaction, probably due to activation of a counterregulating pathway. Protein kinase A (PKA) was identified as a downstream target of TGR5 activation. In contrast, inhibition of phospholipase C and phosphoinositide 3-kinase did not prevent stimulating effects of OLA. Involvement of exchange protein directly activated by cAMP 2 (Epac2) or farnesoid X receptor (FXR2) was ruled out by experiments with knockout mice. The proposed pathway was not influenced by local glucagon-like peptide 1 (GLP-1) secretion from α-cells, shown by experiments with MIN6 cells, and a GLP-1 receptor antagonist. In summary, these data clearly demonstrate that activation of TGR5 in β-cells stimulates insulin secretion via an AC/cAMP/PKA-dependent pathway, which is supposed to interfere with SSC by affecting K and Ca currents and thus membrane potential.
Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD.
Termite F, Archilei S, DAmbrosio F, Petrucci L, Viceconti N, Iaccarino R Antioxidants (Basel). 2025; 14(1).
PMID: 39857390 PMC: 11759774. DOI: 10.3390/antiox14010056.
Bile acid metabolism in type 2 diabetes mellitus.
Cadena Sandoval M, Haeusler R Nat Rev Endocrinol. 2025; .
PMID: 39757322 DOI: 10.1038/s41574-024-01067-8.
Zizzari P, Castellanos-Jankiewicz A, Yagoub S, Simon V, Clark S, Maitre M Mol Metab. 2024; 91():102071.
PMID: 39603503 PMC: 11650306. DOI: 10.1016/j.molmet.2024.102071.
Lei S, Liu G, Wang S, Zong G, Zhang X, Pan L Mol Nutr Food Res. 2024; 68(22):e2400451.
PMID: 39520336 PMC: 11605789. DOI: 10.1002/mnfr.202400451.
Wasim M, Bergonzi M Pharmaceutics. 2024; 16(6).
PMID: 38931816 PMC: 11206505. DOI: 10.3390/pharmaceutics16060692.